ANTIGENIC AND MOLECULAR CHARACTERIZATION OF THE FUSION GLYCOPROTEIN OF RSV

呼吸道合胞病毒是引起下呼吸道疾病的最常见原因。 全世界幼儿中的肠道疾病。它的F糖蛋白 病毒是保护性免疫反应的重要靶点之一； 然而，免疫是不完全的，会发生反复感染。因此， 这个实验室的主要工作是构建一个详细的表位。 RSV F糖蛋白的图谱，然后评估RSV的抗原变异 F-中和和融合表位。融合的基因 呼吸道合胞病毒A2株糖蛋白及14株单抗抗性的研究 突变体已经被克隆和测序。来自60多个克隆的信息 已经被分析过，以确定对 参与中和和融合的表位。我们成功地在 确定A抗原点5个表位的氨基酸组成， 1个表位位于抗原位点AB，1个表位位于B位点，1个表位位于 C位单抗推导的氨基酸序列比较 A亚群、B亚群和B亚群具有F序列的抗体抗性突变体 牛呼吸道合胞病毒株显示，残留物涉及大部分A位点 C表位在所有菌株中都是保守的。这与之形成鲜明对比 到位于高变区的B位表位。这个 由B位MARM定义的氨基酸的变化也同样在 18537株(B亚群病毒)以及两种牛呼吸道合胞病毒株。 在接下来的一年里，我们建议评估对RSV F的免疫反应 免疫后和自然感染后抗原位点A、B和C。

Respiratory syncytial virus is the most common cause of lower respiratory tract disease in young children worldwide. The F glycoprotein of this virus is one of the important targets of a protective immune response; however immunity is incomplete and repeated infections occur. Therefore, a major effort of this laboratory has been to construct a detailed epitope map of the RSV F glycoprotein and then evaluate antigenic variation of the F-neutralization and fusion epitopes. The gene for the fusion glycoprotein of the A2 strain of RSV and 14 monoclonal antibody resistant mutants has been cloned and sequenced. Information from over 60 clones has been analyzed in order to identify the amino acids contributing to the epitopes involved in neutralization and fusion. We were successful in determining amino acids that contribute to 5 epitopes in antigenic site A, one epitope in antigenic site AB, 1 epitope in site B and one epitope in site C. Comparison of the deduced amino acid sequence for the monoclonal antibody resistant mutants with F sequences for subgroup A, subgroup B and bovine strains of RSV show that residues involved in most of the site A and C epitopes are conserved among all the strains. This is in contrast to the site B epitope which is located in a hypervariable region. The change in amino acid defined by the site B MARM is likewise changed in the 18537 strain (a subgroup B virus) as well as both bovine strains of RSV. During the next year we propose to evaluate the immune response to RSV F antigenic sites A, B and C following immunization and natural infection.